

# Zomato shares to list today

PRESS TRUST OF INDIA  
New Delhi, Jult 22

**ONLINE FOOD ORDERING** platform Zomato, which last week closed its mega initial public offering raising over ₹9,000 crore, will list on the stock exchanges on Friday, days ahead of its earlier schedule of the next week.

The firm had indicated a window from July 23 to July 27 for listing, and has now decided to list on Friday, a source said.

“Effective Friday, July 23, 2021, the equity shares of Zomato Limited shall be listed and admitted to dealings on the Exchange in the list of ‘B’ Group of Securities,” the BSE said in a notice.

The company fixed the



price at the higher end of the offer band of ₹72-76 for 71.92 crore shares. The IPO of Zomato was India's biggest initial share sale offer since March 2020.

While qualified institutional buyers or QIBs bid almost 52 times the quota reserved for them, non-institutional investors sought 640 crore shares against their

quota of 19.43 crore. Retail investors bid 7.45 times against the 12.96 crore shares reserved for them.

The only category not fully subscribed was shares reserved for company employees, who sought just 62% of the 65 lakh shares reserved for them.

The IPO was opened for subscription on July 14 in a price band of ₹72-76 per

share. It closed on July 16.

The IPO, which will give Zomato valuation of ₹64,365 crore, is being touted as the second-biggest since SBI Cards and Payment Services' ₹10,341 crore issue in March 2020.

The Zomato IPO comprised a fresh issue of equity shares worth ₹9,000 crore and an offer-for-sale (OFS) worth ₹375 crore by existing investor Info Edge (India), which is the parent company of Naukri.com, according to the information provided in the draft red herring prospectus.

Zomato has said it will utilise the IPO proceeds for funding organic and inorganic growth initiatives and general corporate purposes.

KRISHANA PHOSCHEM LIMITED					
Regd. Off: 5-0-28, Basement, R.C. Vyas Colony, Shilwara, 311001 Rajasthan					
Website: www.krishnaphoschem.com, Email: secretarial@krishnaphoschem.com					
CIN No.: L24124RJ2004PLC019288   Ph: 01482-237104, Fax: 01482-239638					
Unaudited Financial Results for the Quarter Ended 30th June 2021					
(Regulation 47(1)(b) of the SEBI (LODR) Regulations, 2015)					
S. No.	Particulars	Quarter ended		Year Ended	
		30.06.2021	31.03.2021	30.06.2020	31.03.2021
		Unaudited	Audited	Unaudited	Audited
1	Total Income From Operation	5,319.19	5,379.42	4,688.97	19,009.89
2	Net Profit / (Loss) for the period (before tax, and Exceptional and/or Extraordinary Items)	939.42	667.11	434.98	2,839.83
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary Items)	939.42	667.11	434.98	2,839.83
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary Items)	646.66	480.70	286.26	1,958.35
5	Total Comprehensive Income for the period (Comprising Profit/Loss for the period (after tax) and other Comprehensive Income (after tax))	646.66	475.29	286.26	1,952.94
6	Equity Share Capital	2,740.00	2,610.00	2,499.00	2,610.00
7	Other Equity (Reserves)				12,190.93
8	Earning Per Share (of Rs. 10/- each) (for continuing and discontinued operations) (not annulsated)				
1. Basic		2.44	1.90	1.16	7.83
2. Diluted		2.43	1.75	1.09	7.15

Note: (a). The unaudited financial results of the company for the quarter ended June 30, 2021 have been reviewed by the Audit Committee and approved by the Board of Directors at its meetings held on 22nd July, 2021. The same have also been subjected to Limited Review by the Statutory Auditors. (b). The above financial results are prepared in accordance with Indian Accounting Standards (IND AS) as prescribed under section 133 of the companies Act, 2013 read with relevant rules issued there under. (c). The above is an extract of the detailed financial results for the quarter ended 30th June 2021 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the websites of the Stock Exchange www.nseindia.com and Company's websites www.krishnaphoschem.com. For and on behalf of the Board of Directors Sd/- (Sunit Kohari) Whole Time Director & CFO DIN: 02055969

Dated: 22-07-2021

Place: Bhilwara

**Tyche Industries Limited**

Registered Office: C-21/A, Road No. 9, Film Nagar, Jubilee Hills, Hyderabad 500 096  
Ph. No. 040-23541688, Email: cs@tycheindustries.net

**NOTICE**

(For the kind attention of shareholders of the Company)

**TRANSFER OF SHARES OF THE COMPANY TO DEMAT ACCOUNT OF THE IEPF AUTHORITY**

Notice is hereby given that in compliance with the provisions of Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 and section 124(6) of the Companies Act 2013, which came into effect from 7<sup>th</sup> September, 2016, the Company is mandated to transfer all such shares in the name of Investor Education and Protection Fund (IEPF) Account in respect of which dividends has not been paid or claimed for seven consecutive years (2013-14 to 2019-20).

Notice is further given that in accordance with the provisions of the Rules, individual notice has already been sent to respective Shareholders at their latest available addresses with the Company inter alia providing the details of shares being transferred to IEPF Account.

The concerned Shareholders are requested to claim the unpaid/unclaimed dividend amounts with full bank account particulars as intimated individually failing which their shares shall be transferred to IEPF.

In case the concerned Shareholders wish to claim the shares after transfer to IEPF Suspense Account, a separate Application can be made to the IEPF Authority, in the form IEPF-5, as prescribed under the Rules and the same is available at IEPF website i.e www.iepf.gov.in.

In case you need any information/clarification, please contact us at cs@tycheindustries.net or at 040-23541688.

For Tyche Industries Limited  
Sd/-  
G Ganesh Kumar  
Managing Director  
DIN: 01009765

**Dated: 22/07/2021**

**Place: Hyderabad**

## ICICI Lombard Q1 net dives 62% on high Covid claims

FE BUREAU  
Kolkata, July 22

**ICICI LOMBARD GENERAL** Insurance on Thursday said its net profit for the first quarter of this fiscal fell 61.91% year-on-year to ₹151.63 crore as Covid-related health claims stood at a whopping ₹602 crore. The net profit for the year-ago period was ₹398.10 crore. During Q1FY21, the impact of the pandemic-related health claims was ₹20 crore.

“During the quarter ended June 30, 2021 the company has witnessed significantly higher number of reported Covid 19 health claims in second wave in comparison with the wave one. Accordingly, the company has made necessary provision required for these claims. The company will continue to closely monitor any changes to the estimates basis future economic conditions,” the general insurer said in a stock exchange filing.

Gross premium written during the April-June period grew 12.18% y-o-y to ₹3,807.56 crore as against ₹3,394.21 crore in the same period last year.

Gross direct premium income (GDIPI) stood at ₹3,733 crore in Q1FY22 compared to ₹3,302 crore in Q1FY21, a growth of 13.0%. “This was in line with the industry growth,” ICICI Lombard said.

“Combined ratio stood at 121.3% in Q1FY2022 compared to 99.7% in Q1FY2021, primarily driven by Covid-19 pandemic during the quarter. The combined ratio includes Covid-19 impact on health book of ₹6.02 billion in Q1FY2022 as against ₹0.20 billion in Q1FY2021 and ₹3.39 billion in FY2021,” the filing said.

The non-life insurer’s solvency ratio was 2.76x at June 30, 2021 as against 2.90x at March 31, 2021. It was higher than the minimum regulatory requirement of 1.50x.

## Coffee exports declining, Covid causes shift in consumption patterns: Report

FE BUREAU  
Kochi, July 22

**INDIA'S COFFEE EXPORTS** are seen declining for the past few years and fell to a nine-year low partly due to COVID-19. Drip Capital, a global trade finance company, said on Thursday. The ‘Coffee Report’ by the fintech company, based in Palo Alto, mentions that the pandemic led to a shift in consumption patterns and sales of coffee machines soared as coffee enthusiasts turned towards making the beverage at home rather than venturing outside.

India is the eighth-largest producer and exporter of coffee by volume. As per the Directorate General of Foreign Trade, India exported nearly \$720 million worth of coffee in FY21, out of which 42% mainly constituted Robusta coffee beans exports.

However, coffee exports have declined at a CAGR of -3% between FY12 and FY-21, according to the report. “The fall can partly be attributed to Covid-19, wherein in FY19-20, India’s overall coffee exports reached a nine-year low in dollar value terms and plummeted by 44% in April 2020. Moreover, the crisis significantly impacted green coffee beans’ shipments in March 2020, which is the crucial period for Robusta coffee harvesting and exports,” Pushkar Mukewar, co-founder and CEO, Drip Capital, said.

The report says that India could benefit significantly from value addition across the various stages of coffee processing.

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.

### PUBLIC ANNOUNCEMENT



## STAR HEALTH AND ALLIED INSURANCE COMPANY LIMITED

Our Company was incorporated as Star Health and Allied Insurance Company Limited, a public limited company, at Chennai under the Companies Act, 1956 on June 17, 2005 and was granted the certificate of incorporation by the Registrar of Companies, Tamil Nadu at Chennai (“RoC”). Our Company was granted its certificate for commencement of business on December 9, 2005 by the RoC. For details see, “History and Certain Corporate Matters” on page 183 of the Draft Red Herring Prospectus dated July 21, 2021 (“DRHP”).

**Registered and Corporate Office:** No. 1, New Tank Street, Valluvarakkottam High Road, Nungambakkam, Chennai, Tamil Nadu - 600 034, India; **Tel:** +91 44 2828 8800, **Website:** www.starhealth.in; **Contact Person:** Jayashree Sethuraman, Company Secretary and Compliance Officer; **E-mail:** investors@starhealth.in; **Corporate Identity Number:** U66010TN2005PLC056649; **IRDAI Registration Number:** 129

### OUR PROMOTERS: SAFECROP INVESTMENTS INDIA LLP, WESTBRIDGE AIF I AND RAKESH JHUNJHUNWALA

INITIAL PUBLIC OFFER OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹10 EACH (“EQUITY SHARES”) OF STAR HEALTH AND ALLIED INSURANCE COMPANY LIMITED (“COMPANY” OR “ISSUER”) FOR CASH AT A PRICE OF ₹[●] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹[●] PER EQUITY SHARE) AGGREGATING UP TO ₹[●] MILLION (THE “OFFER”) COMPRISING A FRESH ISSUE OF UP TO [●] EQUITY SHARES AGGREGATING UP TO ₹20,000 MILLION (THE “FRESH ISSUE”) AND AN OFFER FOR SALE OF UP TO 60,104,677 EQUITY SHARES, INCLUDING UP TO 30,683,553 EQUITY SHARES BY SAFECROP INVESTMENTS INDIA LLP (“PROMOTER SELLING SHAREHOLDER”), UP TO 137,816 EQUITY SHARES BY KONARK TRUST, UP TO 9,518 EQUITY SHARES BY MPMPL TRUST (“PROMOTER GROUP SELLING SHAREHOLDERS”) UP TO 7,680,371 EQUITY SHARES BY APIS GROWTH 6 LIMITED, UP TO 4,110,652 EQUITY SHARES BY MIO IV STAR, UP TO 7,438,564 EQUITY SHARES BY UNIVERSITY OF NOTRE DAME DU LAC, UP TO 4,110,652 EQUITY SHARES BY MIO STAR, UP TO 2,509,099 EQUITY SHARES BY ROC CAPITAL PTY LIMITED, UP TO 1,476,140 EQUITY SHARES BY VENKATASAMY JAGANNATHAN, UP TO 1,804,312 EQUITY SHARES BY SAI SATISH AND UP TO 144,000 EQUITY SHARES BY BERJIS MINOO DESAI (COLLECTIVELY, THE “OTHER SELLING SHAREHOLDERS” AND COLLECTIVELY WITH THE PROMOTER SELLING SHAREHOLDER AND PROMOTER GROUP SELLING SHAREHOLDERS ARE REFERRED TO AS THE “SELLING SHAREHOLDERS”), AND SUCH EQUITY SHARES, THE “OFFERED SHARES”) AGGREGATING UP TO ₹[●] MILLION (THE “OFFER FOR SALE”), THE OFFER SHALL CONSTITUTE [●]% OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY. THE OFFER INCLUDES A RESERVATION OF UP TO [●] EQUITY SHARES, AGGREGATING UP TO ₹[●] MILLION (CONSTITUTING UP TO [●]% OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL, FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES (“EMPLOYEE RESERVATION PORTION”), THE OFFER LESS THE EMPLOYEE RESERVATION PORTION IS HEREINAFTER REFERRED TO AS THE “NET OFFER”. THE OFFER AND THE NET OFFER SHALL CONSTITUTE [●]% AND [●]%, RESPECTIVELY, OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THE FACE VALUE OF EQUITY SHARES IS ₹10 EACH. THE PRICE BAND AND THE MINIMUM BID LOT SHALL BE DECIDED BY OUR COMPANY AND THE SELLING SHAREHOLDERS IN CONSULTATION WITH THE GLOBAL CO-ORDINATORS AND BOOK RUNNING LEAD MANAGERS (“GCBLRLMS”), BOOK RUNNING LEAD MANAGERS (“BRLMS”) AND CO-BOOK RUNNING LEAD MANAGERS (“CO-BRLMS”) AND WILL BE ADVERTISED IN [●] EDITIONS OF [●], AN ENGLISH NATIONAL DAILY NEWSPAPER, [●] EDITIONS OF [●], A HINDI NATIONAL DAILY NEWSPAPER AND [●] EDITIONS OF [●], A TAMIL DAILY NEWSPAPER (TAMIL BEING THE REGIONAL LANGUAGE OF TAMIL NADU, WHERE OUR REGISTERED AND CORPORATE OFFICE IS LOCATED) EACH WITH WIDE CIRCULATION AT LEAST TWO WORKING DAYS PRIOR TO THE BID/OFFER OPENING DATE AND SHALL BE MADE AVAILABLE TO THE BSE LIMITED (“BSE”) AND THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED (“NSE”), AND TOGETHER WITH BSE, THE “STOCK EXCHANGES”) FOR THE PURPOSE OF UPLOADING ON THEIR RESPECTIVE WEBSITES IN ACCORDANCE WITH THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED (THE “SEBI ICDR REGULATIONS”).

In case of any revision in the Price Band, the Bid/ Offer Period will be extended by at least three additional Working Days after such revision in the Price Band, subject to the Bid/ Offer Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company and the Selling Shareholders may, in consultation with the GCBLRLMS, BRLMS and the Co-BRLMS, for reasons to be recorded in writing, extend the Bid/ Offer Period for a minimum of three Working Days, subject to the Bid/ Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/ Offer Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges, by issuing a public notice, and also by indicating the change on the respective websites of the GCBLRLMS, BRLMS and the Co-BRLMS and at the terminals of the Syndicate Members and by intimation to the Designated Intermediaries and the Sponsor Bank.

The Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended (“SCRR”) read with Regulation 31 of the SEBI ICDR Regulations and in compliance with Regulation 6(2) of the SEBI ICDR Regulations wherein not less than 75% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers (“QIBs”) (the “QIB Portion”), provided that our Company and the Selling Shareholders in consultation with the GCBLRLMS, BRLMS and the Co-BRLMS may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the QIB Portion. One-third of the Anchor Investor Portion shall be reserved for domestic Mutual Funds, subject to valid Bids being received from the domestic Mutual Funds at or above the Anchor Investor Allocation Price. 5% of the QIB Portion (excluding the Anchor Investor Portion) shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders (other than Anchor Investors), including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5% of the QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining QIB Portion for proportionate allocation to QIBs. Further, not more than 15% of the Net Offer shall be available for allocation on a proportionate basis to Non-Institutional Bidders and not more than 10% of the Net Offer shall be available for allocation to RIBs in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. Further, Equity Shares will be allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids received from them at or above the Offer Price. All Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount (“ASBA”) process providing details of their respective bank account (including UPI ID for RIBs using UPI Mechanism), in which the corresponding Bid Amounts will be blocked by the SCSBs or the Sponsor Bank, as applicable. Anchor Investors are not permitted to participate in the Offer through the ASBA process. For details, see “Offer Procedure” on page 372 of the DRHP.

This public announcement is being made in compliance with the provisions of Regulation 26(2) of the SEBI ICDR Regulations to inform the public that our Company is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares pursuant to the Offer and has filed the DRHP dated July 21, 2021 with the SEBI on July 22, 2021.

Pursuant to Regulation 26(1) of the SEBI ICDR Regulations, the DRHP filed with SEBI shall be made public for comments, if any, for a period of at least 21 days from the date of such filing by hosting it on the website of SEBI at www.sebi.gov.in, websites of the Stock Exchanges i.e. BSE and NSE at www.bseindia.com, www.nseindia.com, respectively and the websites of the Global Co-ordinators and Book Running Lead Managers (“GCBLRLMS”), i.e. Kotak Mahindra Capital Company Limited, Axis Capital Limited, BofA Securities India Limited, Citigroup Global Markets India Private Limited, ICICI Securities Limited at https://investmentbank.kotak.com, www.axiscap.in, www.ml-india.com, www.online.citibank.com/rhtm/citigroupglobalscreen1.htm and www.icicisecurities.com, respectively and the websites of the Book Running Lead Managers (“BRLMS”), i.e. CLSA India Private Limited, Credit Suisse Securities (India) Private Limited and Jefferies India Private Limited at www.india.clsa.com, www.credit-suisse.com and www.jefferies.com, respectively and the websites of the Co-Book Running Lead Managers (“Co-BRLMS”), i.e. Ambit Private Limited, DAM Capital Advisors Limited, IIFL Securities Limited and SBI Capital Markets Limited at www.ambit.co, www.damcapital.in, www.iiflcap.com and www.sbicaps.com, respectively. Our Company invites the public to give their comments on the DRHP filed with SEBI, with respect to disclosures made in the DRHP. The members of the public are requested to send a copy of the comments to SEBI, to our Company Secretary and Compliance officer of our Company and/or the GCBLRLMS, BRLMS and the Co-BRLMs at their respective addresses mentioned herein. All comments must be received by our Company and/or the Company Secretary and Compliance officer of our Company and/or the GCBLRLMS, BRLMS and the Co-BRLMs at their respective addresses mentioned herein below in relation to the Offer on or before 5.00 p.m. on the 21<sup>st</sup> day from the aforesaid date of filing of the DRHP with SEBI.

Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Offer unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, investors must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares in the Offer have not been recommended or approved by the Securities and Exchange Board of India (“SEBI”), nor does SEBI guarantee the accuracy or adequacy of the contents of the Draft Red Herring Prospectus. Specific attention of the investors is invited to “Risk Factors” on page 23 of the DRHP.

The IRDAI does not undertake any responsibility for the financial soundness of our Company or for the correctness of any of the statements made or opinions expressed in this connection. Any approval by the IRDAI under the IRDAI Issuance of Capital Regulations (as defined in “Definitions and Abbreviations”) shall not in any manner be deemed to be or serve as a validation of the representations by our Company in the offer document.

Any decision to invest in the Equity Shares described in the DRHP may only be taken after a Red Herring Prospectus has been filed with RoC and must be made solely on the basis of such Red Herring Prospectus. The Equity Shares, when offered through the Red Herring Prospectus, are proposed to be listed on the Stock Exchanges. The Equity Shares, when offered through the Red Herring Prospectus, are proposed to be listed on BSE and NSE.

For details of the share capital and capital structure of our Company, see “Capital Structure” on page 71 of the DRHP. The liability of the members of our Company is limited. For details of the main objects of our Company as contained in the Memorandum of Association, see “History and Certain Corporate Matters” on page 183 of the DRHP.

GLOBAL CO-ORDINATORS AND BOOK RUNNING LEAD MANAGERS TO THE OFFER					REGISTRAR TO THE OFFER
<b>Kotak Mahindra Capital Company Limited</b> 1 <sup>st</sup> Floor, 27 BKC, Plot No. 27, G Block, Pandurang Budhkar Marg, Worli, Mumbai - 400 051, Maharashtra, India Tel: +91 22 4336 0000 E-mail: starhealth ipo@kotak.com Investor grievance e-mail: kmccredressal@kotak.com Website: https://investmentbank.kotak.com Contact Person: Ganesh Rane SEBI Registration No: INM000008704	<b>Axis Capital Limited</b> Axis House, Level 1, C-2 Wadia International Centre, Pandurang Budhkar Marg, Worli, Mumbai - 400 025, Maharashtra, India Tel: +91 22 4325 2183 E-mail: starhealth ipo@axiscap.in Investor grievance e-mail: complaints@axiscap.in Website: www.axiscap.in Contact Person: Simran Gadh SEBI Registration No: INM000012029	<b>BofA Securities India Limited</b> Ground Floor, A Wing One BKC, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051, Maharashtra, India Tel: +91 22 6632 8000 E-mail: dg.star_ipo@bofa.com Investor grievance e-mail: dg.india_merchantbanking@bofa.com Website: www.ml-india.com Contact Person: Deepa Salvi SEBI Registration No: INM000011625	<b>Citigroup Global Markets India Private Limited</b> 1202, 12 <sup>th</sup> Floor, First International Finance Centre, G-Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 098, Maharashtra, India Tel: +91 22 6175 9999 E-mail: starhealth ipo@citi.com Investor grievance e-mail: investors.cgmb@citi.com Website: www.online.citibank.co.in/rhtm/citigroupglobalscreen1.htm Contact Person: Shashank Pandey SEBI Registration No: INM000010718	<b>ICICI Securities Limited</b> ICICI Centre, H. T. Parekh Marg, Churchgate, Mumbai - 400 020, Maharashtra, India Tel: +91 22 2288 2460 E-mail: star ipo@icicisecurities.com Investor grievance e-mail: customercare@icicisecurities.com Website: www.icicisecurities.com Contact Person: Anurag Byas/ Kristina Dias SEBI Registration No: INM000011179	<b>KFin Technologies Private Limited</b> Selenium, Tower B, Plot No- 31 and 32, Financial District, Nanaknagar, Serlingampally, Hyderabad Rangareddy - 500 032, Telangana, India Tel: +91 40 6716 2222/180034 54001 E-mail: starhealth ipo@kfintech.com Investor grievance e-mail: einward.ris@kfintech.com Website: www.kfintech.com Contact Person: M Inruli Krishna SEBI Registration No.: INM000002221
BOOK RUNNING LEAD MANAGERS TO THE OFFER			CO-BOOK RUNNING LEAD MANAGERS TO THE OFFER		
<b>CLSA India Private Limited</b> 8/F Dalamal House, Nariman Point, Mumbai - 400 021, Maharashtra, India Tel: +91 22 6650 5050 E-mail: starhealth ipo@clsa.com Investor grievance e-mail: investor.helpdesk@clsa.com Contact Person: Rahul Choudhary / Prachi Chandgotia Website: www.india.clsa.com SEBI Registration No.: INM000010619	<b>Credit Suisse Securities (India) Private Limited</b> 9 <sup>th</sup> Floor, Ceejay House, Plot F Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai - 400 018, Maharashtra, India Tel: +91 22 6777 3885 E-mail: list.starhealth ipo@credit-suisse.com Investor grievance e-mail: list.igpeller-bnkg@credit-suisse.com Website: www.credit-suisse.com Contact Person: Abhishek Joshi SEBI Registration No.: INM000011161	<b>Jefferies India Private Limited</b> 42/43, 2 North Avenue Maker Maxity, Bandra-Kurla Complex, Bandra (East), Mumbai - 400 051, Maharashtra, India Tel: +91 22 4356 6000 E-mail: starhealth ipo@jefferies.com Investor grievance e-mail: jipl.grievance@jefferies.com Website: www.jefferies.com Contact Person: Aman Puri SEBI Registration No.: INM000011443	<b>Ambit Private Limited</b> Ambit House, 449 Senapati Bapat Marg, Lower Parel, Mumbai - 400 013, Maharashtra, India Tel: +91 22 6623 3000 E-mail: starhealth ipo@ambit.co Investor grievance e-mail: customerservicemb@ambit.co Website: www.ambit.co Contact Person: Nikhil Bhiwapurkar SEBI Registration No.: INM000010585	<b>DAM Capital Advisors Limited (Formerly IDFC Securities Limited)</b> One BKC, Tower C, 15 <sup>th</sup> Floor, Unit No.1511, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051, Maharashtra, India Tel: +91 22 4202 2500 E-mail: starhealth ipo@damcapital.in Investor grievance e-mail: complaint@damcapital.in Contact Person: Chandresh Sharma SEBI Registration Number: MB/INM000011336	<b>IIFL Securities Limited</b> 10 <sup>th</sup> Floor, IIFL Centre, Kamala City, Senapati Bapat Marg, Lower Parel (West), Mumbai - 400 013, Maharashtra, India Tel: +91 22 4646 4600 E-mail: starhealth ipo@iiflcap.com Investor grievance e-mail: ig_ib@iiflcap.com Contact Person: Ujjwal Kumar/ Harshvardhan Jain SEBI Registration Number: MB/INM000010940

All capitalised terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Draft Red Herring Prospectus.

Place: Chennai  
Date: July 22, 2021

**STAR HEALTH AND ALLIED INSURANCE COMPANY LIMITED** is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares and has filed the DRHP dated July 21, 2021 with SEBI on July 22, 2021. The DRHP shall be available on the website of SEBI at www.sebi.gov.in, websites of the Stock Exchanges i.e. BSE and NSE at www.bseindia.com and www.nseindia.com, respectively, and is available on the websites of the GCBLRLMS, i.e. Kotak Mahindra Capital Company Limited, Axis Capital Limited, BofA Securities India Limited, Citigroup Global Markets India Private Limited, ICICI Securities Limited at https://investmentbank.kotak.com, www.axiscap.in, www.ml-india.com, www.online.citibank.com/rhtm/citigroupglobalscreen1.htm and www.icicisecurities.com, respectively and the websites of the BRLMS, i.e. CLSA India Private Limited, Credit Suisse Securities (India) Private Limited and Jefferies India Private Limited at www.india.clsa.com, www.credit-suisse.com and www.jefferies.com, respectively and the websites of the Co-BRLMS, i.e. Ambit Private Limited, DAM Capital Advisors Limited, IIFL Securities Limited and SBI Capital Markets Limited at www.ambit.co, www.damcapital.in, www.iiflcap.com and www.sbicaps.com, respectively. Bidders should note that investment in equity shares involves a high degree of risk and for details relating to the same, please see the section entitled “Risk Factors” on page 23 of the DRHP. Potential Bidders should not rely on the DRHP for making any investment decision. The Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”) or any applicable state securities laws in the United States and, unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. Accordingly, the Equity Shares are being offered and sold (i) within the United States, only to persons reasonably believed to be “qualified institutional buyers” (as defined in Rule 144A under the U.S. Securities Act) in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act, and (ii) outside the United States, in offshore transactions in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales are made. There will be no public offering of the Equity Shares in the United States.

For **STAR HEALTH AND ALLIED INSURANCE COMPANY LIMITED**  
On behalf of the Board of Directors  
Sd/-  
Company Secretary and Compliance Officer



